

Nidhi Tandon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9100402/publications.pdf>

Version: 2024-02-01

24
papers

263
citations

840776

11
h-index

940533

16
g-index

24
all docs

24
docs citations

24
times ranked

450
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective evaluation of the utility of magnetic resonance imaging in patients with nonâ€MRIâ€conditional pacemakers and defibrillators. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 2931-2939.	1.7	3
2	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, 41.	6.2	24
3	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E117-E120.	4.1	13
4	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	2.5	17
5	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiâ€parametric flow cytometry method. <i>American Journal of Hematology</i> , 2019, 94, 424-430.	4.1	11
6	Primary systemic amyloidosis in patients with WaldenstrÃ¶m macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	7.2	28
7	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2019, 33, 730-738.	7.2	20
8	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019, 94, 455-464.	3.0	16
9	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. <i>Leukemia</i> , 2018, 32, 1421-1426.	7.2	8
10	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. <i>Leukemia</i> , 2018, 32, 1243-1246.	7.2	12
11	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2018, 53, 326-333.	2.4	4
12	The evolution of stem-cell transplantation in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 123-133.	2.5	31
13	Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). <i>American Journal of Hematology</i> , 2018, 93, 17-22.	4.1	11
14	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	1.4	1
15	Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 153-158.	0.6	0
16	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	4.1	24
17	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	3.0	4
18	Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, 8, 35.	1.2	30

#	ARTICLE	IF	CITATIONS
19	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 2082-2082.	1.4	1
20	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. Blood, 2016, 128, 3272-3272.	1.4	1
21	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. Blood, 2016, 128, 3317-3317.	1.4	3
22	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. Blood, 2016, 128, 4627-4627.	1.4	1
23	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. Blood, 2016, 128, 3338-3338.	1.4	0
24	Impact of Melphalan-Based Chemotherapy on Stem Cell Collection in Patients with Light Chain Amyloidosis. Blood, 2016, 128, 2187-2187.	1.4	0